Claritin-D adds asthma safety labeling; Hoechst and Schering settle in Claritin ad dispute.
SCHERING-PLOUGH CLARITIN-D ADDS ASTHMA SAFETY DATA TO LABELING Feb. 5: the company announced that it is updating the Claritin-D label with information regarding the safety of its loratadine/pseudoephedrine product in seasonal allergic rhinitis patients with concomitant asthma. Prescribing information for Claritin-D now lists results of a study in patients with asthma and states: "This supports the safety of administering Claritin-D to seasonal allergic rhinitis patients with asthma." In the six-week, placebo-controlled study, patients with rhinitis and mild-to-moderate asthma had improvements in allergy symptoms with no decrease in pulmonary function, Schering reported.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth